A woman with dangerously high cholesterol has been getting a shot every few weeks for years — effective, but one more needle to manage on top of everything else. As of this week, patients like her have a new option: the same kind of cholesterol-lowering treatment, but as a once-daily pill instead of an injection.
On July 16, 2026, the FDA approved Lipfendra (enlicitide), made by Merck, making it the first oral PCSK9 inhibitor ever cleared for use in the US. It’s a genuinely new category of pill, not just another statin, and it’s arriving for a condition that affects a large share of American adults.
Key Takeaways
- Lipfendra is the first pill version of a PCSK9 inhibitor, a class of cholesterol drug previously available only as an injection.
- In clinical trials, it lowered LDL (“bad”) cholesterol by 56-59% compared to placebo, on top of any statin a patient was already taking.
- It’s approved for adults with high cholesterol, including a genetic form called heterozygous familial hypercholesterolemia (HeFH).
- Side effects were generally similar to placebo, though some patients had diarrhea or dizziness.
- It’s not yet proven that Lipfendra itself reduces heart attacks or strokes — that data is still being collected in an ongoing trial.
Why a Pill Version Matters
About one in four American adults has high LDL cholesterol, a major driver of heart attacks and strokes. Statins are the usual first treatment, but some people don’t get enough benefit from statins alone, can’t tolerate them, or have a genetic condition like HeFH that keeps their cholesterol stubbornly high regardless. For those patients, injectable PCSK9 inhibitors like Repatha and Praluent have been available for about a decade, working by blocking a protein (PCSK9) that would otherwise interfere with the liver’s ability to clear cholesterol from the blood. Lipfendra uses that same mechanism, but Merck built it as a small circular molecule (called a macrocyclic peptide) that can survive digestion and be taken as a tablet — a technical hurdle that’s kept this class of drug injection-only until now.
What the Trials Showed
The approval was based on two Phase 3 trials involving thousands of patients. In the larger trial, Lipfendra reduced LDL cholesterol by 56% more than placebo after 24 weeks, on top of whatever statin patients were already taking; in patients with the genetic HeFH form of high cholesterol, the reduction was 59%. Side effects were similar in frequency to placebo overall, though HeFH patients reported diarrhea (7%) and dizziness (9%) at somewhat higher rates. Adherence in the trials was notably high, with 97% of participants taking all or nearly all of their prescribed doses — likely helped by the simplicity of a daily pill compared to a periodic injection.
What’s Still Unproven
It’s worth being precise about what this approval does and doesn’t show. Lipfendra clearly lowers LDL cholesterol — that’s what got it approved. What hasn’t been directly proven yet is whether taking Lipfendra itself lowers a patient’s risk of an actual heart attack or stroke, as opposed to just improving a blood test number. Merck has a separate outcomes trial underway to answer that question, though LDL-lowering itself has a long track record of translating into fewer cardiovascular events with other drugs in this same class. It’s also worth noting that PCSK9 inhibitors as a category haven’t sold as well as originally expected since the injectable versions launched a decade ago, so how quickly this pill gets adopted — and what it will cost patients — remains to be seen.
What Comes Next
Lipfendra was approved through the FDA’s Commissioner’s National Priority Voucher program, a newer pathway designed to speed up review for certain medicines, and Merck has said it’s working to get the drug to patients quickly. It also beats a rival oral PCSK9 pill from AstraZeneca to market, so more competition in this space may follow.
Source: U.S. Food and Drug Administration, “FDA Approves First Oral Therapy That Inhibits PCSK9 To Lower Bad Cholesterol in Adults With High Cholesterol,” July 16, 2026; Merck, LIPFENDRA (enlicitide) approval announcement, July 2026.